184 related articles for article (PubMed ID: 18980992)
21. Serum YKL-40 and colorectal cancer.
Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
Br J Cancer; 1999 Mar; 79(9-10):1494-9. PubMed ID: 10188896
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of YKL-40 and interleukin-18 and their relationship to disease severity in patients with preeclampsia.
Seol HJ; Lee ES; Jung SE; Jeong NH; Lim JE; Park SH; Hong SC; Oh MJ; Kim HJ
J Reprod Immunol; 2009 Jan; 79(2):183-7. PubMed ID: 19200605
[TBL] [Abstract][Full Text] [Related]
23. Concentrations of the acute phase reactants high-sensitive C-reactive protein and YKL-40 and of interleukin-6 before and after treatment in patients with acromegaly and growth hormone deficiency.
Andreassen M; Vestergaard H; Kristensen LØ
Clin Endocrinol (Oxf); 2007 Dec; 67(6):909-16. PubMed ID: 17727678
[TBL] [Abstract][Full Text] [Related]
24. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects.
Johansen JS; Lottenburger T; Nielsen HJ; Jensen JE; Svendsen MN; Kollerup G; Christensen IJ
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2603-8. PubMed ID: 18843001
[TBL] [Abstract][Full Text] [Related]
25. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.
Svane IM; Pedersen AE; Johansen JS; Johnsen HE; Nielsen D; Kamby C; Ottesen S; Balslev E; Gaarsdal E; Nikolajsen K; Claesson MH
Cancer Immunol Immunother; 2007 Sep; 56(9):1485-99. PubMed ID: 17285289
[TBL] [Abstract][Full Text] [Related]
26. Cross-sectional evaluation of YKL-40 serum concentrations in patients with systemic sclerosis. Relationship with clinical and serological aspects of disease.
La Montagna G; D'Angelo S; Valentini G
J Rheumatol; 2003 Oct; 30(10):2147-51. PubMed ID: 14528508
[TBL] [Abstract][Full Text] [Related]
27. [The importance of determining the prognostic marker YKL-40 in serum and tissues].
Łata E; Gisterek I; Matkowski R; Szelachowska J; Kornafel J
Pol Merkur Lekarski; 2010 Jun; 28(168):505-8. PubMed ID: 20642115
[TBL] [Abstract][Full Text] [Related]
28. Serum YKL-40, a new prognostic biomarker in cancer patients?
Johansen JS; Jensen BV; Roslind A; Nielsen D; Price PA
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):194-202. PubMed ID: 16492905
[TBL] [Abstract][Full Text] [Related]
29. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement.
Nordenbaek C; Johansen JS; Halberg P; Wiik A; Garbarsch C; Ullman S; Price PA; Jacobsen S
Scand J Rheumatol; 2005; 34(4):293-7. PubMed ID: 16195162
[TBL] [Abstract][Full Text] [Related]
30. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.
Mylin AK; Rasmussen T; Johansen JS; Knudsen LM; Nørgaard PH; Lenhoff S; Dahl IM; Johnsen HE;
Eur J Haematol; 2006 Nov; 77(5):416-24. PubMed ID: 16930142
[TBL] [Abstract][Full Text] [Related]
31. Increased serum levels of YKL-40 in patients with inflammatory bowel disease.
Koutroubakis IE; Petinaki E; Dimoulios P; Vardas E; Roussomoustakaki M; Maniatis AN; Kouroumalis EA
Int J Colorectal Dis; 2003 May; 18(3):254-9. PubMed ID: 12673492
[TBL] [Abstract][Full Text] [Related]
32. Serum YKL-40 as a marker for cervical adenocarcinoma.
Mitsuhashi A; Matsui H; Usui H; Nagai Y; Tate S; Unno Y; Hirashiki K; Seki K; Shozu M
Ann Oncol; 2009 Jan; 20(1):71-7. PubMed ID: 18723551
[TBL] [Abstract][Full Text] [Related]
33. Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer.
Johansen JS; Christensen IJ; Jørgensen LN; Olsen J; Rahr HB; Nielsen KT; Laurberg S; Brünner N; Nielsen HJ
Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):621-6. PubMed ID: 25597749
[TBL] [Abstract][Full Text] [Related]
34. High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients.
Mylin AK; Abildgaard N; Johansen JS; Andersen NF; Heickendorff L; Standal T; Gimsing P; Knudsen LM
Eur J Haematol; 2008 Apr; 80(4):310-7. PubMed ID: 18182077
[TBL] [Abstract][Full Text] [Related]
35. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.
Tanwar MK; Gilbert MR; Holland EC
Cancer Res; 2002 Aug; 62(15):4364-8. PubMed ID: 12154041
[TBL] [Abstract][Full Text] [Related]
36. Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease.
Kronborg G; Ostergaard C; Weis N; Nielsen H; Obel N; Pedersen SS; Price PA; Johansen JS
Scand J Infect Dis; 2002; 34(5):323-6. PubMed ID: 12069012
[TBL] [Abstract][Full Text] [Related]
37. Early detection and prognosis of ovarian cancer using serum YKL-40.
Dupont J; Tanwar MK; Thaler HT; Fleisher M; Kauff N; Hensley ML; Sabbatini P; Anderson S; Aghajanian C; Holland EC; Spriggs DR
J Clin Oncol; 2004 Aug; 22(16):3330-9. PubMed ID: 15310777
[TBL] [Abstract][Full Text] [Related]
38. A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker.
Kruit A; Grutters JC; Ruven HJ; van Moorsel CC; van den Bosch JM
Respir Med; 2007 Jul; 101(7):1563-71. PubMed ID: 17236752
[TBL] [Abstract][Full Text] [Related]
39. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response?
Coskun U; Yamac D; Gulbahar O; Sancak B; Karaman N; Ozkan S
Neoplasma; 2007; 54(4):348-52. PubMed ID: 17845129
[TBL] [Abstract][Full Text] [Related]
40. Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease.
Zheng JL; Lu L; Hu J; Zhang RY; Zhang Q; Chen QJ; Shen WF
Atherosclerosis; 2010 Jun; 210(2):590-5. PubMed ID: 20056225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
